Comparable efficacy and safety of dolutegravir/ lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: The DOLCE study.

Conference Reports for NATAP

HIV Drug Therapy Glasgow 2024
10-13 November


Comparable efficacy and safety of dolutegravir/ lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: The DOLCE study.

	NCT04880395